In an attempt t o decrease the relapse rate after bone marrow transplantation (BMT) for advanced acute leukemia, we initiated studies using '3'1-labeled anti-CD45 antibody (BC81 t o deliver radiation specifically t o hematopoietic tissues, followed by a standard transplant preparative regimen. Biodistribution studies were performed in 23 patients using 0.5 mg/kg trace '3'1-labeled BC8 antibody. The BC8 antibody was cleared rapidly from plasma with an initial disappearance half-time of 1.5 f 0.2 hours, presumably reflecting rapid antigen-specific binding. The mean radiation absorbed doses (cGy/mCi l3lI administered) were as follows: marrow, 7.1 +-0.8; spleen, 10.8 f 1.4; liver, 2.7 f 0.2; lungs, 2.1 C 0.1; kidneys, 0.7 f 0.1; and total body, 0.4 f 0.03. Patients with acute myelogenous leukemia (AML) in relapse had a higher marrow dose (11.4 cGy/mCi) than those in remission (5.2 cGy/mCi; P = .001) because of higher uptake and longer
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A
LTHOUGH BONE marrow transplantation (BMT) can cure many patients with acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL), those with advanced disease have a very high relapse rate despite the high-dose chemoradiotherapy used in most preparative regimens. Attempts have been made to increase cure rates by increasing the dose of the chemotherapy and/or radiation delivered. The dose response of leukemic cells to radiation in vivo has been demonstrated by two studies, one in AML in first remission' and a second in chronic myeloid leukemia (CML) in chronic phase,' where patients receiving HLAmatched related marrow were randomized between treatment with cyclophosphamide (CY) and fractionated total body irradiation (TBI) at either 12 or 15.75 Gy. In both studies the higher dose of TB1 was associated with a significantly lower relapse rate (12% v 35% for AML; 0% v 25% for CML), but in both studies nonrelapse mortality rates were higher for patients receiving the higher radiation dose, resulting in no difference in long-term, disease-free survival.
The cure rate for leukemia might improve if more radia-cyclophosphamide (CY) and 12 Gy total body irradiation (TBI). Nine of 13 patients with AML or refractory anemia with excess blasts (RAEB) and two of seven with acute lymphocytic leukemia (ALL) are alive disease-free at 8 t o 41 months (median, 17 months) after BMT. Toxicity has not been measurably greater than that of CY/TBI alone, and the maximum tolerated dose has not been reached. This study demonstrates that with the use of %BC8 substantially greater doses of radiation can be delivered t o hematopoietic tissues as compared with liver, lung, or kidney, which may improve the efficacy of marrow transplantation.
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tion could be delivered selectively to marrow and other sites of leukemic involvement while sparing the normal nonhematopoietic organs. Several investigators have used monoclonal antibodies to deliver radioisotope to sites of hematopoietic malignancies in both preclinical'." and clinical""' studies. Two studies have used "'I-labeled monoclonal antibody reactive with the CD33 antigen to treat patients with AM""'.'' In both studies it was demonstrated that this approach could deliver radiotherapy with relative specificity to the marrow in some patients, but the degree of specificity was limited. Success in this approach appeared limited by low CD33 expression on target cells and by internalization of the antibody-antigen complex leading to rapid deiodination and release of I3'I from the target tissues.
CD45 is a cell-surface glycoprotein broadly expressed by all circulating leukocytes and lymphocytes and by approximately 70% of nucleated cells in normal marrow, but not by cells outside the lymphoid and hematopoietic lineages.?' CD45 expression has been detected in 85% to 90% of cases of AML and ALL (Andres and Kadin," Caldwell et al," and D.C.M., unpublished observations, September 1990). Normal and malignant hematopoietic cells show strong CD45 expression (2 X IO' antibody binding sites per cell), and the antigen does not internalize after antibody binding. Our previous biodistribution studies in mice'* and nonhuman primatesz9 showed that '"I-labeled anti-CD45 antibody delivers two-to threefold more radiation to marrow, up to 12-fold more to spleen, and two-to eightfold more to lymph nodes than to critical normal organs.
Based on these encouraging preclinical studies, we initiated a Phase I clinical trial to study the biodistribution of I3'Ilabeled anti-CD45 antibody in patients undergoing marrow transplantation for advanced acute leukemia. We were interested in determining factors that might influence the biodistribution of antibody, such as disease (AML v ALL) and disease state (remission v relapse). Patients were first given 1-131-ANTI-CD45 ANTIBODY THERAPY OF LEUKEMIA 1123 trace 13'I-labeled anti-CD45 antibody for determination of antibody biodistribution and estimation of radiation absorbed doses delivered to target and normal organs. In this dose escalation trial, patients in whom the estimated dose of radiation delivered to the target organs (marrow and spleen) was greater than that to any critical normal organ (liver, lung, and kidney) were eligible for treatment with I3'I-labeled anti-CD45 antibody followed by cyclophosphamide (CY), 12 Gy TBI, and infusion of HLA-matched related allogeneic or previously stored autologous marrow. We report the results of the biodistribution studies in our first 23 patients, demonstrating that with '3'I-labeled anti-CD45 antibody it is possible to deliver two to four times more radiation to the marrow and spleen than to the normal organs receiving the highest dose, and that with this technique more than 20 Gy of radiotherapy can be delivered to marrow in addition to the usual CY-TB1 regimen without excessive toxicity.
MATERIALS AND METHODS

Patient selection.
Patients referred to the Fred Hutchinson Cancer Research Center (Seattle, WA) for marrow transplantation for AML or ALL beyond first remission or with refractory anemia with excess blasts (RAEB) were eligible for this study. Patients in relapse could not have a circulating blast count greater than 5,OOO/pL, although control of circulating blasts with drugs such as hydroxyurea was allowed. Major organ dysfunction, seropositivity for HIV, allergies to mouse protein or to iodine, or antibody specific for mouse Ig were reasons for exclusion. Patients were required to have either an HLA-identical family marrow donor or cryopreserved autologous marrow. In most cases, autologous marrow had been incubated with 4-hydroxyperoxycyclophosphamide (4-HQ3'' or treated with monoclonal antibodies." Patients were informed of the nature of this Phase I study and signed a consent form approved by the Human Subjects Committee of the University of Washington (Seattle, WA) and the Institutional Review Board of the Fred Hutchinson Cancer Research Center.
Antibody production, pur$carion, cznd radiolabeling. BC8 is a hybridoma that secretes a murine IgGl antibody reactive with all CD45 isoforms. The hybridoma was developed and provided by Dr Claudio Anasetti of the Fred Hutchinson Cancer Research Center. The murine hybridoma was adapted for large scale antibody production by Brunswick (San Diego, CA), where hybridoma culture supernatant was produced in hollow fiber bioreactors and antibody was purified by saturated ammonium sulfate precipitation and ion exchange chromatography. DT and LS antibodies are murine IgGl antibodies reactive with idiotypes expressed by B-cell lymphomas. These purified antibodies were produced and provided by IDEC Pharmaceuticals (San Diego, CA) for use as nonspecific (ie, negative control) antibodies. The BC8 antibody was labeled with I3'I (New England Nuclear, Boston, MA, specific activity 8.0 mCi/mg) and DT or LS with '''1 (New England Nuclear, Boston, MA; specific activity, 17.2 mCi/mg) by the chloramine-T method and was purified and tested as previously des~ribed.''.~~ Determination of antibody biodistribution and radiation absorbed dose. Before the administration of the trace-labeled biodistribution dose, the patient's serum was tested for the presence of human antimouse antibody (HAMA) using an enzyme-linked immunosorbent assay (ELISA) as previously p~b1ished.l~ Patients in relapse were eligible only if the leukemic blasts expressed CD45 as detected by BC8 antibody with indirect immunofluorescence assays using a fluorescein isothiocyanate (F1TC)-labeled goat anti-mouse IgG + M F(ab')* second-stage reagent (Tago, Inc, Burlingame, CA). Patients in remission did not require leukemic cell phenotyping before entry on study.
Lung, liver, spleen, and kidney volumes were calculated from chest and abdominal computed tomography or magnetic resonance image scans. The first 16 patients also had technetium-99m liverspleen, lung, and kidney radionuclide scans for precise organ localization as previously des~ribed,'~ but these scans were omitted for subsequent patients as organs were readily visualized after 13'I-BC8 administration (liver, spleen), easily localized (lungs), or did not demonstrate appreciable uptake of radionuclide (kidney). Patients were given oral iodide drops to block thyroid uptake of free I3'I.
For biodistribution studies, 0.5 mgkg BC8 antibody was labeled with 5 to 10 mCi I3'I and combined with 0.2 mgkg DT or LS antibody labeled with 2 to 5 mCi Patients were premedicated with 25 to 50 mg intravenous diphenhydramine, 50 to 100 mg intravenous hydrocortisone, and 650 mg oral acetaminophen. BC8 antibody was infused at 5 mg/h for the first 30 minutes and then increased to 10 mg/h as tolerated. The diphenhydramine dose was repeated every 2 hours and other medications (such as meperidine) were administered as needed for chills. The antibody infusion rate was slowed or stopped for symptoms such as throat tightness or severe chills.
Blood samples were obtained hourly during the antibody infusion and 0, 30, 60, 90, and 120 minutes (and in some cases, 4 and 8 hours) after the infusion, followed by daily samples for 3 to 5 days. Samples were analyzed for specific and nonspecific serum antibody concentrations. Clearance curves were fit manually for determination of the long-term clearance half-time, and where a more rapid early clearance was appreciable, the early-phase, rapid-clearance halftime. Samples were also analyzed for immunoreactivity of infused antibody by measuring percent bindable "'I counts with excess numbers of RAJ1 cells, for quantifiable mouse IgG using an ELISA, and for trichloracetic acid (TCA)-precipitable counts as previously A bone marrow biopsy was obtained at hour 24 (or at hour 48 if the hour-24 sample was inadequate), weighed, and gamma counted for determination of percent injected dose per gram (% lD/g). The marrow localization index (LI) was calculated with reference to a concomitant serum sample:
At hour 0 (end of infusion) and then daily for 3 days, quantitative gamma images were collected with a dedicated GE 400 AT largefield-of-view camera with a high energy collimator (Fig 1) . Regions of interest including liver, lungs, spleen, kidneys (if visible), and at least two marrow sites (usually humeral head and ilium) were imaged using a 180" opposing view quantitative planar te~hnique.~' Results were corrected for whole-body thickness attenuation, radioactive decay, and electronic drift and compared with a known amount of I3'I for quantitation. The % ID/g of I3'I-BC8 in marrow determined by biopsy was corrected for the presence of trabecular bone and fat by a multiplication factor of 2 (as approximately half of the total biopsy weight consists of trabecular bone and fat, where antibody does not bind) for purposes of scaling the marrow clearance The marrow volume assumed for dosimetry purposes was 1,120 g red marrow for a standard adult male and 1,050 g red marrow for a standard adult female. Time-activity curves generated for each organ were used to calculate estimated radiation absorbed doses using methods consistent with those recommended by the Society of Nuclear Medicine's Special Committee on Medical Internal Radiation Dose3537 as previously described." Statistical comparisons were performed using the Student's t test (SPSS for Windows 6.0, SPSS Inc, Chicago, IL).
For personal use only. on October 3, 2017. by guest www.bloodjournal.org Therap. Patients were eligible for a therapy dose of '"l-BC8 if the biodistribution study estimated that the target organs (marrow and spleen) would receive a greater radiation absorbed dose than any normal organ (favorable biodistribution). The amount of '"I used for therapy was calculated to deliver a specified dose to the normal organ receiving the highest radiation absorbed dose, with this dose being escalated in groups of no fewer than three patients. The starting dose of radiation delivered to this normal organ by "'1-BC8 antibody was 3.5 Gy. Dose escalation was allowed if none of three or no more than one of six patients experienced grade 111 (lifethreatening) or IV (fatal) regimen-related toxicity'" at a given dose. Patients received the therapy dose on average 7 days after the biodistribution dose. The therapy dose was administered in specially constructed lead-lined isolation rooms. Administration of the therapy dose was identical to the biodistribution dose in timing and premedications. Patients remained in isolation (usually 3 to 4 days) until the total body '"1 activity was less than 30 mCi. The day of the therapy dose was day -14. Patients were then admitted to a marrow transplant ward and received CY 60 mgkg intravenously on days -8 and -7, followed by TB1 given as a single 2-Gy fraction daily from days -6 to -1 (dose rate, 5 to 8 cGy/min) for a total dose of 12 Gy. Marrow (allogeneic or autologous) was infused on day 0. Allogeneic recipients received cyclosporine and methotrexate for graft-versus-host disease prophylaxis. All patients received routine post-transplant supportive care. The results are current as of August 31, 1994.
RESULTS
Biodisrriburion studies. Twenty-three patients have been entered on study. Age, sex, disease and FAB classification, disease status, and marrow source for patients are presented in Table I . Fifteen patients had AML (eight in second or third remission and seven in relapse), and seven had ALL [four in second complete remission (CR)].
Administration of the '%BC8 antibody biodistribution dose was accompanied by tolerable side effects in 78% of patients. Patients developed shaking chills that responded to slowing of the infusion and administration of meperidine. Fever above 38.5"C was uncommon. Other symptoms included nausea, vomiting, diarrhea, headache, and mild hypotension responsive to intravenous crystalloid administration. Transient dyspnea andor throat tightness occurred in 26% of patients and resolved after the antibody infusion was temporarily slowed or halted and diphenhydramine with or with- out hydrocortisone was administered. In two patients, the antibody infusion was stopped after a total dose of 0.2 mg/ kg because of dyspnea (UPN 5961) or chest tightness (UPN 7708). Both patients requiring cessation of antibody infusion were receiving antibody at rates over 7.5 mgih when they developed symptoms (UPN 5961, 20 mgih; UPN 7708, 10 mg/h). All other patients were able to receive a full dose of 0.5 mgkg. The dose rate generally did not exceed 10 mgih of BC8 antibody, and some patients tolerated only 5 to 7.5 mg/h. Antibody infusions for those receiving a full dose lasted between 3 and 8.9 hours (median, 5.2 hours). Biodistribution data from the two patients receiving 0.2 mgkg did not differ from the patients receiving 0.5 mgkg and are included in the data analysis reported below.
In 10 patients the first 7.5 mg of antibody (ie, the first hour of antibody infusion) was administered as unlabeled or cold antibody. This preclearing dose was given in order to test whether this approach could decrease hepatic uptake of radiolabeled circulating white blood cells by causing sequestration of cells by unlabeled antibody. This approach was based on observations made in a canine model?'
The peak (ie, end of infusion) concentration of BC8 antibody in plasma was 0.0057% +-0.001% ID/g, significantly lower than nonspecific antibody (0.0225% t 0.001% ID/g; P = .006). This presumably reflects the rapid antigen-specific binding of the anti-CD45 antibody. The anti-CD45 antibody clearance demonstrated a rapid initial disappearance phase (t = 1.4 2 0.1 hours) in 19 patients. In four patients, serum clearance data were either not adequate to define early clearance (two patients) or did not demonstrate a rapid initial disappearance phase (two patients). There was no correlation between the length of the antibody infusion and the presence or length of a rapid initial disappearance phase. The slower disappearance phase (tl/2 = 30.0 ? 2.6 hours) was similar to that of the nonspecific antibody (27.8 +-2.9 hours). There were no differences in peak BC8 antibody concentration or clearance between groups of patients with AML or ALL, remission or relapse, or between patients receiving or not receiving a preclearing dose of unlabeled antibody (data not shown).
Pharmacokinetic and biodistribution results for marrow are summarized in Table 2 . The average initial (ie, hour 0, end of infusion) marrow uptake of 13'I-BC8 was 0.0301% % 0.002% ID/g. The average marrow half-life (biologic halflife; ie, half-life of antibody alone, not accounting for radioactive decay) of the radiolabeled antibody was 41.4 % 2.7 hours, and the average L1 was 47.7 2 6.1. There were no differences seen in initial uptake or half-life among patients with ALL in remission or relapse or AML in remission. Patients with AML in relapse were different, with higher initial antibody uptake (0.0406% ? 0.005% ID/g) as compared with remission AML patients (0.0262% t 0.002% ID/ g; P = .019) and longer retention of radioiodine in marrow (marrow t'/*, 54.3 t 6.1 hours) than in remission patients (35.9 ? 2.4 hours; P = ,008). Their L1 was also higher (63.7 5 17.4) than in AML patients in remission (35.7 ? 5.9; P = .06). There were no differences in the level of CD45 antigen expression on the leukemic blasts of relapse patients with AML or ALL as determined by flow microfluorimetry (data not shown).
Although the goal of delivering a preclearing dose of unlabeled antibody was to decrease the uptake of radionuclide by the liver, there was no difference in the hour 0 liver uptake of I 3 ' i between the nonprecleared and the precleared group (0.0126% 2 0.001% ID/g v 0.0129% 2 0.001% ID/ g; P = .43), or in the (biologic) of 13'1 in the liver (29.5 2 1.7 hours v 31.0 2 2.6 hours; P = .33).
Estimated radiation absorbed doses. The means and ranges of estimated radiation absorbed doses for target organs (marrow and spleen) and critical normal organs (lungs, liver, and kidneys) calculated from the trace-labeled antibody infusions are shown in Table 3 . Overall, the mean radiation absorbed dose (cGy/mCi I3'I administered) for marrow was 7.1 ? 0.8; for spleen, 10.8 ? 1.4; for liver. 2.7 t 0.2; for lungs, 2.1 -+ 0.1; for kidneys, 0.7 ? 0.1; and for total body, 0.4 t 0.03. Thus, the mean therapeutic ratio of radiation delivered to the marrow as compared with the liver was 2.7; to the lung, 3.4; and to the kidney, 11 3 . The liver was the normal organ receiving the highest estimated radiation absorbed dose in all patients except patient 7574, in whom an unusually long retention of radioisotope in the lungs resulted in an estimated lung dose of 3.0 cGy/mCi 'j'l, higher than the 1.7 cGy/mCi received by the liver.
The longer retention of radionuclide in the marrow of patients with AML studied in relapse and the higher initial marrow uptake of I3'I resulted in a significantly higher marrow radiation dose in these patients as compared with those with AML in remission ( 1 1.4 ? 1.5 cGy/mCi v 5.2 t 0.7 cGy/mCi; P = .OOl). As there was not a significant difference in the estimated radiation absorbed dose to the liver between these groups (2.4 t 0.2 cGy/mCi v 2.9 i 0.4 cGy/ mCi; P = .29), the therapeutic ratio of radiation delivered to marrow as compared with the liver was higher for patients with AML in marrow relapse as compared with AML patients in remission (3.6 v 2.1; P < ,001). For ALL, there was no difference between remission and relapse patients in radiation dose to marrow or liver and, therefore, no difference in therapeutic ratio.
The dose to spleen was higher than to marrow on average, but not in all patients. There was appreciable variability between patients in the estimated absorbed dose to liver, with a 2.5-fold range (1.7 to 4.6 mCi/cGy I3'I). There were no apparent factors (remission, relapse, circulating blasts, preclear or no preclear dose) associated with the observed variability in liver dose.
Three patients did not have favorable biodistribution and were not treated on protocol. Patient 5961 relapsed with leukemia cutis. Although a skin biopsy 24 hours after anti- 
Values are means t SE (range).
* Estimated radiation absorbed doses to marrow calculated using published meth0ds.3~"~ Recent proposed methods4' would result in a bwer t f = ,0005 for difference between remission and relapse in patients with AML.
* P = ,025 for difference between AML and ALL in patients in relapse.
marrow dose than noted here (see Discussion).
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From body infusion demonstrated detectable localization of I3'I-BC8 (LI, 3.0), the isotope concentration in the skin was low (0.0013% ID/g), and it was believed that this patient would be best treated with a regimen including total skin irradiation delivered by external beam. Patient 5992 had the lowest marrow uptake and radiation absorbed dose (2.5 cGy/mCi I3'I) with a therapeutic ratio of 0.93 and, therefore, did not meet treatment criteria. Patient 7541 (with primarily refractory AML) had excellent marrow uptake but a relatively low concentration of antibody in a markedly enlarged spleen. An unusually long retention of isotope in the lungs resulted in an estimated therapeutic ratio (spleen to lungs) of 0.90, which did not meet treatment criteria. Therapy and toxicities. Twenty patients had favorable biodistribution of the trace "'I-labeled BC8 antibody and were treated with the same dose of antibody labeled with the amount of I3'I activity calculated to deliver a predetermined irradiation absorbed dose to the normal organ receiving the highest dose (ie, the liver). Table 4 summarizes the calculated activity (millicuries) of I3'I for each patient and the total estimated absorbed radiation doses delivered to liver, bone marrow, and spleen. Administration of the therapy dose of '311-BC8 was associated with symptoms similar to those that occurred with the trace-labeled dose. Some patients had mild to moderate nausea lasting 1 to 3 days after the therapy dose. No other symptoms were noted during the time between the therapy dose of I3'I and the initiation of CY.
The toxicity of the preparative regimen was not appreciably greater than would have been expected with CY and 12.0 Gy TB1 alone (Table 4 ). All patients developed grade I1 mucositis (ie, requiring narcotic therapy). At dose level 1 (3.5 Gy to the normal organ receiving the highest radiation dose), one patient (373 1) developed grade I11 gastrointestinal toxicity characterized by ileus (requiring nasogastric suction) and colonic dilatation with heme-positive diarrhea 16 to 18 days post-transplant. This patient then developed unequivocal gut graft-versus-host disease, which may have been the etiology of his symptoms. For the purposes of this study, this patient was considered to have possible grade I11 regimen-related toxicity. Patient 6538 died of systemic candidia-
on day +20 and was not, therefore, completely evaluable with respect to regimen-related toxicity, necessitating treatment of a seventh patient at this dose level. Thus, of the six evaluable patients at dose level 1, there was one grade 111 toxicity (GI). Patient 7304 treated at dose level 2 (5.25 Cy to the normal organ receiving the highest dose) developed influenza B infection immediately after the therapeutic infusion of antibody and after marrow transplant developed biventricular heart failure resulting in pulmonary edema requiring intubation. He also developed unstable ventricular tachycardia requiring cardioversion. Treatment with radiolabeled antibody was considered an unlikely cause of the cardiac dysfunction because of the rapid clearance of I3'I-BC8 from blood, lack of any cardiac uptake of isotope on imaging, and lack of specific localization to cardiac muscle demonstrated in preclinical macaque studies. Although cardiac function improved, the patient had recurrent fevers and pulmonary infiltrates attributed to viral infection and died on day +40. This patient was considered nonevaluable with respect to toxicity, necessitating treatment of a seventh patient at dose Ievel 2. Thus, of six evaluable patients, none had grade I11 or IV toxicity.
Six patients were treated at dose level 3 (7 Gy to the normal organ receiving the highest dose). Patient 7541 died at day +29 of candida pneumonia, without engraftment and despite the administration of granulocyte colony-stimulating factor (G-CSF). A postmortem marrow biopsy showed minimal myeloid and erythroid engraftment, no megakaryocytes, the presence of macrophages and eosiniphilic debris suggestive of stromal damage, and no leukemic blasts. This patient received the highest estimated radiation absorbed dose to the bone marrow of any patient: 30.7 Cy from '"I-labeled BC8 antibody. It is possible that this radiation dose damaged the supportive marrow microenvironment, thus affecting engraftment. However, this patient also had a high serum methotrexate level in the posttransplant period, which could have contributed to her poor engraftment. None of the other five patients treated at this dose level had grade 111 or IV toxicity.
As the criteria for maximum tolerated dose has not yet been reached (ie, grade 111 to 1V regimen-related toxicity in more than one of six or fewer patients treated), we are continuing to enter patients on this phase I dose-escalation study.
Outcome. Of 10 patients with AML or myelodysplastic syndrome (MDS) evaluable for relapse (ie, patients surviving the first 100 days posttransplant), one relapsed 7 months posttransplant. Nine are surviving disease-free 8 to 41 months posttransplant (median, 17 months). Of six patients with ALL evaluable for relapse, four have relapsed between 0.5 and 12 months after transplant, with two relapse-free survivors 22 and 9 months after BMT.
DISCUSSION
Our study demonstrates that 1311-labeled anti-CD45 antibody can deliver up to four times more radiation to the marrow, and eight times more to the spleen, than to the normal organ receiving the highest radiation dose (the liver). Further, we have shown that at least 7 Gy of radiation can be delivered to the liver via '"I-BC8 antibody, in addition to 120 mgkg CY and 12 C y TBI, with no readily appreciable increased risk of regimen-related toxicity above that expected from CY/TBI alone. This has allowed the delivery of up to 28 Gy to marrow via radiolabeled antibody, in combination with 12 Gy TBI.
There are reasons to believe that this approach might lead to an improved cure rate. The randomized study' comparing two doses of TB1 with a set dose of CY in AML patients in first remission demonstrated that an increase in the dose of TB1 of 3.75 Gy decreased the relapse rate by almost twothirds. The supplemental radiation doses that were delivered by "'1-BC8 antibody to the marrow (4 to 30 Gy) and spleen (7 to 60 Gy) in this study are higher than 3.75 Gy and may improve leukemic cell kill and decrease the rate of relapse after transplantation. While the relative biologic effectiveness of radiation delivered at the low-dose rate using "'Ilabeled antibody is unknown, the supplemental doses delivered to hematopoietic tissue in this study are considerable.
Although follow-up is short, we are encouraged by the finding that only one patient has relapsed of 10 evaluable patients with AML or MDS with a median follow-up of 17 months (range, 8 to 41 months). While fewer patients have been transplanted for ALL using this treatment regimen, the four relapses seen in the six evaluable patients are less encouraging, but three of these four patients had refractory disease (either primary or refractory second relapse) at the time of transplantation, and one was transplanted with autologous marrow.
Larger numbers of patients will be required to define more accurately the factors that influence the biodistribution of '3'I-labeled anti-CD45 antibody. However, for patients with AML, the estimated marrow radiation absorbed dose was higher for patients in marrow relapse at the time of study, both because initial marrow uptake was greater and because retention of the radionuclide was longer. Reasons for this longer retention are unclear. There was no such difference between remission and relapse patients in the smaller number of ALL patients studied.
In this study, the use of a preclearing dose of cold antibody in an attempt to saturate antibody binding sites on circulating white blood cells as well as cause sequestration of antibodycoated cells did not result in any decrease in hour 0 liver uptake of '"I or in estimated hepatic radiation absorbed dose. The dose of cold antibody, 7.5 mg, was the dose given over the first hour of antibody infusion and had been demonstrated to saturate antibody-binding sites on circulating cells and to produce the majority of the fall in circulating white blood cells in initial patients studied (data not shown). The lack of a difference in hepatic uptake and retention of radionuclide between patients receiving or not receiving cold antibody suggests that much of the hepatic localization of antibody may be due to binding of I3'I-labeled BC8 antibody to the CD45 antigen expressed by tissue macrophages in the liver. Similar attempts to use a preclearing dose of anti-CD45 antibody in murine studies have also had no impact on hepatic localization of antibody (D.C.M., unpublished observations, 1993).
Our study showed wide and unpredictable variability in initial uptake and retention of radiolabeled antibody in the liver, causing marked differences between patients in the estimates of hepatic radiation absorbed dose per millicurie I3'I administered. In all treated patients, the liver was the normal organ receiving the highest radiation dose; therefore, the hepatic radiation dose determined the amount of I3'I administered to each patient. The variability of estimated hepatic radiation absorbed dose resulted in a wide range of radioiodine doses at any single level (eg, 149 to 400 mCi at dose level 3), supporting the importance of using individualized trace-labeled biodistribution studies to determine therapy doses.
Radioiodinated CD45-specific antibody was more effective in delivering relatively selective hematopoietic radiation than was CD33-specific antibody in our previous study." Of 23 patients, 20 (87%) achieved favorable biodistribution with the CD45-specific antibody, as compared with four of nine (44%) with the CD33-specific antibody. The average therapeutic ratio of radiation dose received by marrow compared with normal organs receiving the highest dose was 2.7 for patients receiving BC8 antibody, compared with 1.2 for patients receiving p67 antibody, the CD33-specific antibody ( P = .003). The average radiation dose to the marrow was higher with BC8 antibody (7.1 cGy/mCi I3'I administered) than with p67 antibody (1.6 cGy/mCi; P < .001). The somewhat higher initial uptake of radionuclide (0.030% ID/g BC8 antibody v 0.021% ID/g p67 antibody; P = .06) may reflect the higher average antigen expression of CD45 on marrow cells compared with CD33. In our studies, there was also significantly longer retention of '3'1 in marrow when delivered via the noninternalizing BC8 antibody (t'/* = 41.4 hours) as compared with p67 antibody (t% = 21.4 hours; P .001), which rapidly internalizes after antibody binding. Using a different anti-CD33 antibody, M195, Scheinberg et aIz0 reported concentrations of I3'I in marrow biopsies at 1 hour and 2 to 4 days after antibody infusion which suggested longer retention time in some patients than we have observed. Although reasons for a difference between these two antibodies that appear to detect the same or close-by epitopes are not clear, a direct comparison of the retention time of I3'I delivered by M195 antibody and p67 antibody would be of interest. Papadopoulos et d4' have combined radiation delivered via "'I-labeled M195 antibody with busulfan and CY in a phase I study of patients with advanced or refractory AML undergoing allogeneic marrow transplantation. In that study. the delivery of up to 160 mCilm2 of I3'I was well tolerated.
Recently, a different method has been proposed for calculating estimated marrow-absorbed radiation doses4' Use of the proposed methodology would result in a lower estimated marrow dose. The two methods for calculation of absorbed dose differ with respect to the S factor for marrow, a factor that defines the absorbed fraction of energy resulting from radioisotope deposited in a tissue, divided by the mass of the tissue. We have used the same S factors to calculate radiation absorbed doses to target and nontarget tissues in all of our studies of radioimmunotherapy for the past 5 adopted."637 The consistency with which these calculations have been performed allows comparison between different Years,'4.2'.24 from the time these factors were originally antibodies at our institution, such as those described above between BC8 (anti-CD45 antibody) and p67 (anti-CD33 antibody). The generation of any proposed S factor depends on the assumptions that are made about factors influencing the deposition of energy from an isotope in tissue, and no experimental in vivo evidence exists to prove or disprove the assumptions made for marrow in either method. Until the actual accuracy of any of the methods for estimating marrow absorbed radiation dose is determined experimentally (using, for example, implantable microdosimeters), the most appropriate data to consider for purposes of comparison of the biodistribution of different radioimmunoconjugates may be the actual concentrations of isotope in target and normal tissues over time, as these data are subject to many fewer assumptions.
In our preclinical studies of the biodistribution of I3'Ianti-CD45 antibodies in the macaque,29 the red marrow concentration of anti-CD45 antibody was two-to fourfold greater than that in liver 48 hours after antibody infusion, as directly determined from tissue samples obtained at autopsy. In the clinical study described here, the time-activity curve of concentration of radioisotope over time in red marrow is scaled to the actual concentration in a marrow biopsy 24 to 48 hours after antibody infusion, while the concentration of isotope in liver is determined by quantitative gamma camera techniques. The average ratio of red marrow concentration to liver concentration of '"I-BC8 antibody at the end of antibody infusion in the patients reported here was 2.4 2 0.2, with a range of 1.0 to 3.9. These ratios are evidence that there was more radioisotope in red marrow than in liver in most patients. However, the problem with the calculations of estimated radiation absorbed doses for target and nontarget tissues in any current radioimmunotherapy study remains that none of the proposed methods have been completely validated experimentally.
In summary, our current study demonstrates that substantially greater doses of radiation can be delivered to hematopoietic tissues, as compared with liver, lung, or kidney, using '3'I-labeled CD45-specific antibody. The toxicity of this supplemental radiation has not been appreciably greater than that of CYiTBI alone, and dose escalation is continuing in this study. Further experience with the use of radiolabeled antibody for treatment of leukemia, and particularly the ability of radiolabeled anti-CD45 antibody to produce immunosuppression by irradiating lymphoid tissue, may allow us to decrease the amount of systemic therapy in the preparative regimen, including the dose of TBI. Moreover, problems related to clinical use of a gamma-emitting isotope may be rendered less cumbersome by the use of alternative isotopes such as Is6Re or wY, which emit little or no gamma energy and, thus, pose fewer radiation safety risks. Efforts to increase the radiation dose delivered to marrow by radiolabeled anti-CD45 antibody, such as the possibility of using hematopoietic growth factors to improve initial radionuclide uptake in remission marrow by increasing cellularity, might improve the therapeutic ratio, further increasing the efficacy of this therapy. Overall, this approach offers the possibility of augmenting antileukemic therapy without increasing toxicity, thus potentially improving the cure rate after BMT for acute leukemia.
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